Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.26 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

21 22 Next >

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗

February 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

Expert Ratings for Intellia Therapeutics ↗

January 24, 2023

Via Benzinga

The Latest Analyst Ratings for Intellia Therapeutics ↗

January 04, 2023

Via Benzinga

Analyst Ratings for Intellia Therapeutics ↗

December 02, 2022

Via Benzinga

Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates ↗

November 14, 2022

Via Benzinga

Recap: Intellia Therapeutics Q3 Earnings ↗

November 03, 2022

Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗

January 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

Via InvestorPlace

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

January 24, 2023

The growth-focused money manager is making moves.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Friday ↗

January 20, 2023

Friday saw 23 companies set new 52-week lows.

Via Benzinga

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗

January 07, 2023

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

Via The Motley Fool

7 Analysts Have This to Say About Intellia Therapeutics ↗

October 11, 2022

Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023 ↗

January 24, 2023

Via Benzinga

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗

December 30, 2022

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023 ↗

January 19, 2023

Via Benzinga

3 Mid-Caps That Could Double in 2023

December 15, 2022

Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months.

Via MarketBeat

7 ‘Next Big Things’ for Investors to Buy for 2023 ↗

December 13, 2022

The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.

Via InvestorPlace

Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday ↗

December 02, 2022

Via Benzinga

NTLA Stock Falls as Intellia Therapeutics Announces Public Offering ↗

December 01, 2022

Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares.

Via InvestorPlace

Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing ↗

November 28, 2022

Here's how Ark Invest's top holdings have performed in 2022.

Via Investor's Business Daily

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94% ↗

November 15, 2022

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.

Via Benzinga

Earnings Preview For Intellia Therapeutics ↗

November 02, 2022

Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

3 Cathie Wood Stocks to Buy and Hold for 10 Years ↗

October 19, 2022

The risks are formidable, but the chances of a massive gain are too much to pass up.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

The Top 5 Stocks Cathie Wood Is Buying This Week ↗

September 23, 2022

Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022 ↗

September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago...

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.